Additionally, the consistent reduction in markers such as interleukin-6 and improvements in lipid metabolism and muscle mass across several studies support the systemic benefits of EGCG, potentially aiding in the broader management of MS symptoms and co-morbidities. Here, IL6 is linked to myeloid sarcoma.